当代绝经激素治疗与心血管疾病风险:瑞典全国注册模拟目标试验
该研究基于瑞典全国注册数据,采用模拟目标试验设计,纳入2007至2020年间919614名50-58岁、既往两年未使用激素治疗的女性,通过138个嵌套试验比较八种激素治疗方案启动者与未启动者。意向治疗分析显示,替勃龙与心血管疾病风险升高相关(HR 1.52,95%CI 1.11-2.08),替勃龙和口服雌孕激素治疗与缺血性心脏病风险升高相关(HR 1.46,95%CI 1.00-2.14;HR 1.21,95%CI 1.00-1.46);口服连续、序贯及单用雌激素治疗均与静脉血栓栓塞风险升高相关。符合方案分析中,替勃龙还与脑梗死(HR 1.97,95%CI 1.02-3.78)和心肌梗死(HR 1.94,95%CI 1.01-3.73)风险升高相关。这些发现提示不同激素组合和给药途径对心血管疾病风险的影响存在差异。
要点
- 替勃龙启动者心血管疾病风险高于未启动者(HR 1.52,95%CI 1.11-2.08),缺血性心脏病风险亦升高(HR 1.46,95%CI 1.00-2.14)。
- 口服雌孕激素治疗启动者缺血性心脏病风险升高(HR 1.21,95%CI 1.00-1.46)。
- 口服连续雌孕激素治疗静脉血栓栓塞风险升高(HR 1.61,95%CI 1.35-1.92),序贯治疗(HR 2.00,95%CI 1.61-2.49)和单用雌激素治疗(HR 1.57,95%CI 1.02-2.44)亦然。
- 符合方案分析中,替勃龙使用与脑梗死风险升高相关(HR 1.97,95%CI 1.02-3.78)及心肌梗死风险升高相关(HR 1.94,95%CI 1.01-3.73)。
- 共24089名女性随访期间发生事件,其中缺血性心脏病10360例(43.0%)、脑梗死4098例(17.0%)、心肌梗死4312例(17.9%)、静脉血栓栓塞9196例(38.2%)。
适用人群与场景
- 2007年至2020年间年龄50-58岁、既往两年未使用激素治疗的瑞典女性,共919614名。
- 研究基于瑞典全国注册数据,模拟目标试验,非急诊或ICU场景。
研究设计与关键结果
- 研究设计为基于瑞典全国注册的模拟目标试验,共设计138个嵌套试验,从2007年7月至2018年12月每月启动。
- 纳入919614名女性,其中77512名为任何绝经激素治疗启动者,842102名为未启动者。
- 意向治疗分析中,替勃龙启动者心血管疾病风险高于未启动者(HR 1.52,95%CI 1.11-2.08);替勃龙和口服雌孕激素治疗启动者缺血性心脏病风险升高(HR 1.46,95%CI 1.00-2.14;HR 1.21,95%CI 1.00-1.46)。
- 意向治疗分析中,口服连续雌孕激素治疗(HR 1.61,95%CI 1.35-1.92)、序贯治疗(HR 2.00,95%CI 1.61-2.49)和单用雌激素治疗(HR 1.57,95%CI 1.02-2.44)与静脉血栓栓塞风险升高相关。
- 符合方案分析中,替勃龙使用与脑梗死风险升高相关(HR 1.97,95%CI 1.02-3.78)和心肌梗死风险升高相关(HR 1.94,95%CI 1.01-3.73)。
- 随访期间24089名女性发生事件:缺血性心脏病10360例(43.0%)、脑梗死4098例(17.0%)、心肌梗死4312例(17.9%)、静脉血栓栓塞9196例(38.2%)。
证据类型、等级与局限
- 证据类型:基于瑞典全国注册的模拟目标试验(观察性模拟意向治疗及符合方案分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现强调不同激素组合和给药方法对心血管疾病风险的影响存在差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the effect of contemporary menopausal hormone therapy on the risk of cardiovascular disease according to the route of administration and combination of hormones.
DESIGN: Nationwide register based emulated target trial.
SETTING: Swedish national registries.
PARTICIPANTS: 919 614 women aged 50-58 between 2007 and 2020 without hormone therapy use in the previous two years, identified from the Swedish population.
INTERVENTIONS: 138 nested trials were designed, starting each month from July 2007 until December 2018. Using the prescription registry data for that specific month, women who had not used hormone therapy in the previous two years were assigned to one of eight treatment groups: oral combined continuous, oral combined sequential, oral unopposed oestrogen, oral oestrogen with local progestin, tibolone, transdermal combined, transdermal unopposed oestrogen, or non-initiators of menopausal hormone therapy.
MAIN OUTCOME MEASURES: Hazard ratios with 95% confidence intervals were estimated for venous thromboembolism, as well as for ischaemic heart disease, cerebral infarction, and myocardial infarction separately and as a composite cardiovascular disease outcome. Treatment effects were estimated by contrasting initiators and non-initiators in observational analogues to "intention-to-treat" analyses and continuous users versus never users in "per protocol" analyses.
RESULTS: A total of 77 512 women were initiators of any menopausal hormone therapy and 842 102 women were non-initiators. 24 089 women had an event recorded during the follow-up: 10 360 (43.0%) had an ischaemic heart disease event, 4098 (17.0%) had a cerebral infarction event, 4312 (17.9%) had a myocardial infarction event, and 9196 (38.2%) had a venous thromboembolic event. In intention-to-treat analyses, tibolone was associated with an increased risk of cardiovascular disease (hazard ratio 1.52, 95% confidence interval 1.11 to 2.08) compared with non-initiators. Initiators of tibolone or oral oestrogen-progestin therapy had a higher risk of ischaemic heart disease (1.46 (1.00 to 2.14) and 1.21 (1.00 to 1.46), respectively). A higher risk of venous thromboembolism was observed for oral continuous oestrogen-progestin therapy (1.61, 1.35 to 1.92), sequential therapy (2.00, 1.61 to 2.49), and oestrogen-only therapy (1.57, 1.02 to 2.44). Additional results in per protocol analyses showed that use of tibolone was associated with a higher risk of cerebral infarction (1.97, 1.02 to 3.78) and myocardial infarction (1.94, 1.01 to 3.73).
CONCLUSIONS: Use of oral oestrogen-progestin therapy was associated with an increased risk of heart disease and venous thromboembolism, whereas the use of tibolone was associated with an increased risk of ischaemic heart disease, cerebral infarction, and myocardial infarction but not venous thromboembolism. These findings highlight the diverse effects of different hormone combinations and administration methods on the risk of cardiovascular disease.
参考来源
- Johansson T, Karlsson T, Bliuc D, et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024. PMID: 39603704. doi:10.1136/bmj-2023-078784
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。